TUCSON, Ariz., Aug. 4, 2025 /PRNewswire/ — In a U.S. market where fewer than 2% of EMS agencies have implemented prehospital blood programs—and over 70% of those rely on Delta Development Team (DDT) systems—DDT is emerging as the clear leader in a rapidly expanding space. Today, the company announced the successful close of its Series A3 funding round, marking a major milestone in its growth trajectory.
Unlike many startups navigating a tight funding landscape, DDT completed its extended Series A round in just nine months. This momentum is a direct result of its increasing adoption across both civilian and military healthcare sectors, its growing reputation as the gold standard in cold chain technology, and its alignment with evolving protocols that prioritize earlier access to blood in the field.
“This market is transforming fast—and we’re not just keeping pace; we’re driving the shift,” said Montgomery Leija, CEO of Delta Development Team. “From military partnerships to frontline EMS units, our systems are becoming foundational infrastructure for evolving prehospital blood programs.”
The Series A3 round was backed by a mix of strategic capital and non-dilutive funding, including support from the U.S. Air Force’s TACFI (SBIR) program. This funding structure enables DDT to scale quickly while minimizing dilution and operational risk.
Investors
Amongst other investors, this round attracted a consortium of top angel networks known for backing breakthrough healthcare and deep-tech ventures:
About Delta Development Team (DDT)
Delta Development Team is redefining emergency medical care through rugged, field-ready refrigeration, monitoring, and logistics systems. Its mission is to ensure frontline responders have the tools they need to deliver lifesaving blood and biologics when and where they’re needed most.
To learn more, visit deltadevteam.com or contact info@deltadevteam.com.
SOURCE Delta Development Team
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…